Risk Factors for Glaucoma Drainage Device Revision or Removal Using the IRIS Registry.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
08 2022
Historique:
received: 19 11 2021
revised: 16 03 2022
accepted: 23 03 2022
pubmed: 6 4 2022
medline: 27 7 2022
entrez: 5 4 2022
Statut: ppublish

Résumé

To elucidate risk factors for revision or removal of glaucoma drainage devices (GDD) in glaucoma patients in the United States. Retrospective cohort study. IRIS Registry (Intelligent Research in Sight) patients who underwent GDD insertion between January 1, 2013 and December 31, 2018 were included. Various demographic and clinical factors were collected. Kaplan-Meier survival plots, Cox proportional-hazard models utilizing Firth's Penalized Likelihood, and multivariate linear regression models were used. The main outcome measures were hazard ratios (HR) and beta coefficient (β) estimates. A total of 44,330 distinct patients underwent at least 1 GDD implantation, and 3354 of these underwent subsequent GDD revision or removal surgery. With failure defined as GDD revision/removal, factors significantly associated with decreased failure included unknown race (HR = 0.83; P = .004) and unknown ethnicity (HR = 0.68; P < .001). Factors associated with increased risk of GDD revision/removal surgery included presence of chronic angle-closure glaucoma (HR = 1.32; P < .001) and dry eye disease (HR = 1.30; P = .007). Additionally, factors associated with a decreased average time (in days) to GDD revision/removal included male sex (β = -25.96; P = .044), unknown race (β = -55.28; P = .013), and right-eye laterality (β = -38.67; P = .026). Factors associated with an increased average time to GDD revision/removal included having a history of a past eye procedure (β = 104.83; P < .001) and being an active smoker (β = 38.15; P = .024). The size and scope of the IRIS Registry allows for detection of subtle associations between risk factors and GDD revision or removal surgery. The aforementioned demographic and clinical factors may all have an impact on GDD longevity and can inform the treatment options available for glaucoma patients.

Identifiants

pubmed: 35381206
pii: S0002-9394(22)00135-0
doi: 10.1016/j.ajo.2022.03.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

302-320

Subventions

Organisme : NEI NIH HHS
ID : P30 EY003790
Pays : United States

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Nathan E Hall (NE)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

Enchi K Chang (EK)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

Sandy Samuel (S)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

Sanchay Gupta (S)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

Emma Klug (E)

Massachusetts Eye and Ear, Department of Ophthalmology (E.K), Massachusetts Eye and Ear Glaucoma Service, Boston, Massachusetts, USA.

Tobias Elze (T)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

Alice C Lorch (AC)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

Joan W Miller (JW)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V).

David Solá-Del Valle (D)

From Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School (N.E.H, E.K.C, S.S, S.G, T.E, A.C.L, J.W.M, D.S-D.V). Electronic address: david_sola-delvalle@meei.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH